{"id":"eu-simponi","safety":{"commonSideEffects":[{"rate":"37","effect":"Injection site reactions"},{"rate":"7","effect":"Upper respiratory tract infections"},{"rate":"5","effect":"Nasopharyngitis"},{"rate":null,"effect":"Tuberculosis reactivation"},{"rate":null,"effect":"Serious infections"}]},"_chembl":{"chemblId":"CHEMBL5857501","moleculeType":null,"molecularWeight":"542.39"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Simponi (golimumab) is a fully human monoclonal antibody that binds to and neutralizes TNF-alpha, a key pro-inflammatory cytokine. By blocking TNF-alpha, it suppresses the inflammatory cascade underlying autoimmune conditions. This mechanism reduces joint inflammation, systemic inflammation, and disease progression in conditions like rheumatoid arthritis and inflammatory bowel disease.","oneSentence":"Simponi is a TNF-alpha inhibitor that blocks tumor necrosis factor signaling to reduce inflammation in autoimmune diseases.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:46:27.802Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Ankylosing spondylitis"},{"name":"Psoriatic arthritis"},{"name":"Ulcerative colitis"},{"name":"Crohn's disease"}]},"trialDetails":[{"nctId":"NCT05632211","phase":"PHASE1","title":"A Study to Investigate the PK, Safety, and Tolerability Between AVT05, US and EU Simponi® in Healthy Adult Participants","status":"COMPLETED","sponsor":"Alvotech Swiss AG","startDate":"2022-12-16","conditions":"Healthy Adult Subjects","enrollment":336},{"nctId":"NCT05842213","phase":"PHASE3","title":"Comparative, Multicenter Study in Subjects with Rheumatoid Arthritis, ALVOFLEX","status":"COMPLETED","sponsor":"Alvotech Swiss AG","startDate":"2023-03-30","conditions":"Rheumatoid Arthritis","enrollment":502},{"nctId":"NCT04152759","phase":"PHASE1","title":"Comparative Study to Evaluate the Pharmacokinetics of BAT2506 vs Simponi® in Healthy Subjects","status":"COMPLETED","sponsor":"Bio-Thera Solutions","startDate":"2019-09-09","conditions":"Psoriatic Arthritis","enrollment":182},{"nctId":"NCT05046431","phase":"PHASE3","title":"Comparative Study of BAT2506 With Simponi® in Participants With Active Psoriatic Arthritis","status":"COMPLETED","sponsor":"Bio-Thera Solutions","startDate":"2021-05-06","conditions":"Psoriatic Arthritis","enrollment":704},{"nctId":"NCT05332730","phase":"PHASE1","title":"A Study on Pharmacokinetics and Safety of BAT2506 Injection Versus Simponi®","status":"COMPLETED","sponsor":"Bio-Thera Solutions","startDate":"2022-08-01","conditions":"Psoriatic Arthritis","enrollment":375}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"EU Simponi","genericName":"EU Simponi","companyName":"Bio-Thera Solutions","companyId":"bio-thera-solutions","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Simponi is a TNF-alpha inhibitor that blocks tumor necrosis factor signaling to reduce inflammation in autoimmune diseases. Used for Rheumatoid arthritis, Ankylosing spondylitis, Psoriatic arthritis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}